Disruptions in TGF␤ signaling have been implicated in various human cancers, including ovarian cancer. Our goal was to determine whether ovarian cancer cells isolated from patient ascites fluid were growth inhibited by TGF␤1 treatment and further characterize the expression and activity profile of TGF␤/Smad signaling components in human ovarian cancer cells. We found that 9 of 10 primary cultures of ovarian cancer cells (OC2-10) were growth inhibited by 16 pM TGF␤1. O VARIAN CANCER HAS the second highest incidence in gynecological cancers, ranks first in gynecologic cancer-related mortality (5-yr survival rate is ϳ20%), and is the fifth leading cause of cancer death among women (1, 2). If ovarian cancer is detected early, more than 93% of patients survive 5 yr; however, more than 75% of cases are diagnosed at advanced stages with a poor prognosis for survival (American Cancer Society). Most ovarian cancers are believed to arise from the ovarian surface epithelium (OSE), a modified peritoneal mesothelium derived embryologically from the coelomic epithelium (3). Characterizing the pathways that regulate the growth of OSE cells is a necessary first step toward understanding the events that lead to uncontrolled cellular proliferation and the development of ovarian cancer.
O VARIAN CANCER HAS the second highest incidence in gynecological cancers, ranks first in gynecologic cancer-related mortality (5-yr survival rate is ϳ20%), and is the fifth leading cause of cancer death among women (1, 2) . If ovarian cancer is detected early, more than 93% of patients survive 5 yr; however, more than 75% of cases are diagnosed at advanced stages with a poor prognosis for survival (American Cancer Society). Most ovarian cancers are believed to arise from the ovarian surface epithelium (OSE), a modified peritoneal mesothelium derived embryologically from the coelomic epithelium (3) . Characterizing the pathways that regulate the growth of OSE cells is a necessary first step toward understanding the events that lead to uncontrolled cellular proliferation and the development of ovarian cancer.
Human OSE cells express many of the receptors for hormones and growth factors produced by the ovarian surface epithelial, follicular, and stromal cells, leading to the suggestion that epithelial cell activity may be modified by autocrine and paracrine signals (4 -6) . OSE cells often form inclusion bodies within the ovarian cortex, and these are the predominant sites of epithelial dysplasia and cancer formation (3, 7, 8) . It remains unclear what factors influence the transformation of the OSE in the inclusion cysts. Under circumstances in which women have reduced ovulation, such as with multiparity, lactation, and use of oral contraceptives, there is a decreased risk of developing ovarian cancer. The molecular basis for this phenomenon is unknown; however, recent research suggests that oral contraceptives may provide protection against development of ovarian cancer because they induce TGF␤ production in OSE cells, which initiates apoptosis and prevents OSE hyperplasia (9) . Determining whether TGF␤ signaling activity is lost in ovarian cancer will give us insight into OSE cell transformation and may provide a novel basis for the prevention or treatment of ovarian cancer.
In humans, members of the TGF␤ superfamily can modulate growth of normal OSE cells in vitro (4, 10 -12) . Although mutations affecting TGF␤ receptors or their intracellular signaling molecules, the Smad proteins, are implicated in the development of human cancer (13, 14) , the role that TGF␤/ Smad signaling plays in ovarian tumorigenesis is unclear. TGF␤ isoforms (TGF␤1-3) and the type I (T␤RI) and type II (T␤RII) TGF␤ receptor subunits are expressed by normal human OSE, established human ovarian cancer cell lines, and primary ovarian cancer tissue and cells (4, 15, 16) . Ito et al. (17) found that the downstream effectors for TGF␤ signaling Smad2 and Smad4 are expressed in the established human ovarian cancer cell line OVCAR 3. Because normal OSE produce and are growth inhibited by TGF␤, it has been suggested that disruption to the TGF␤ signaling pathway may contribute to ovarian tumorigenesis. Recent reports (16, 18 -20) suggest that deletion or inactivating mutations to components of the TGF␤/Smad signaling pathway occur in human ovarian cancer. By contrast, Hurteau et al. (11) show that primary ovarian cancer cell cultures remain sensitive to the antiproliferative effect of TGF␤, and Rodriguez et al. (21) demonstrate that TGF␤ treatment can enhance invasiveness of ovarian cancer cells through up-regulation of matrix metalloproteinases. Few studies have specifically determined whether primary human ovarian cancer cells maintain a functional TGF␤ signaling pathway (11, 16) . In agreement with Hurteau et al. (11) , we found that 9 of 10 primary cultures of ovarian cancer cells isolated from ascite fluid remained sensitive to TGF␤ growth inhibition and that these cells express all components of the TGF␤/Smad signaling pathway. Further, we show that ovarian cancer cells treated with TGF␤1 up-regulate endogenous TGF␤/Smad target genes including p15
Ink4B , Smad7, and plasminogen activator inhibitor 1 (PAI-1). Our data conclusively demonstrated that most primary human ovarian cancer cells remain sensitive to the antiproliferative effects of TGF␤ in vitro and that the TGF␤/Smad signaling pathway remains functional.
Materials and Methods

Primary human ovarian cancer cells
Institutional approval for research with human materials was received before the initiation of these studies (QEII Health Sciences Center, Research Ethics Committee, no. QE-RS-99-016). Primary human ovarian cancer cells were isolated from ascite specimens by a technique modified from Hirte et al. (22) . Briefly, ascitic fluid containing cells was mixed 1:1 with growth medium (MCDB105/M199 supplemented with 10% heatinactivated FBS and 100 U/ml penicillin/streptomycin). After 3 d, the ascitic fluid supernatant/medium was removed and attached cells were fed growth medium. A total of nine primary ovarian cancer (OC) cultures (OC1-9) were used for all experiments in the present study; however, only data from OC1-3 are shown. Expression of the epithelial marker E-cadherin was detected by RT-PCR analysis of the OC cultures, thus defining them as being derived from OSE and distinguishing them from reactive mesenchyme (23) (24) (25) , a possible contaminant in cell preparations isolated form ascite fluid. Most experiments were performed at culture passages two through six, with the exception of those involving OC1 cells, which have been maintained in long-term culture and are currently at a higher passage number (Ͼ20).
Cell lines
Two ovarian cancer cell lines were used in this study, CaOV3 and SkOV3. Cells were grown in monolayer and maintained in DMEM (Canadian Life Technologies, Inc., Burlington, Ontario, Canada) supplemented with 0.1 mm nonessential amino acids, 10% heat-inactivated FBS (Canadian Life Technologies, Inc.) and penicillin/streptomycin (100 U/ml). Mv1Lu cells were obtained from the American Type Culture Collection (Manassas, VA) and grown in MEM supplemented with 2 mm l-glutamine, 0.1 mm nonessential amino acids, 1 mm sodium pyruvate, 10% heat-inactivated FBS, and penicillin/streptomycin (100 U/ml). Mv1Lu cells are known to stop growing in response to TGF␤ treatment and were used as control cultures for growth curve analyses.
RT-PCR amplification, cRNA probes, and Northern analysis
Total cytoplasmic RNA for RT-PCR was isolated from ovarian cancer cells, cell lines, and tumor tissue using the single-step guanidinium isothiocyanate method (26 INK4B (69 -449), and PAI-1 (159 -717) were subcloned into pCRII.TOPO (Invitrogen, Carlsbad, CA) and the identity of the amplified fragment was verified by manual sequencing.
32 P-Labeled antisense cRNA probes were generated and purified by PAGE.
For Northern analysis primary ovarian cancer cells and ovarian cancer cell lines were treated with 16 pm (0.1 ng/ml) TGF␤1 (Sigma-Aldrich Corp., Oakville, Ontario, Canada) for 4 h. RNA was isolated using the Genelute mammalian total RNA kit (Sigma-Aldrich Corp.). Ten micrograms total RNA was separated on a 1.5% formaldehyde gel and transferred to BrightStar Plus membrane (Ambion, Inc., Austin, TX). Blots were incubated with 1 ϫ 10 6 cpm/ml cRNA probe overnight at 60 C in hybridization buffer (400 mm sodium phosphate, 1 mm EDTA, 0.5% SDS, 1 mg/ml BSA, 0.2 mg/ml yeast tRNA, 50% formamide) and washed at 60 C in wash solution (0.1% SDS, 0.1ϫ standard saline citrate, 1 mm EDTA). Signals were visualized by autoradiography and loading controlled by densitometry and normalized to the signal from glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA. The data shown are representative of two independent experiments.
Western analysis
Total cellular protein was isolated from ovarian cancer cells grown to 70 -80% confluence on 100-mm plates. Cells were washed two times in ice-cold PBS, dissolved in lysis buffer (50 mm Tris-Cl, pH 7.4, 150 mm NaCl, 1 mm EGTA, 1% Nonidet P-40, 0.25% sodium deoxycholate, 1 mm Na 3 VO 4 , 1 mm NaF, protease inhibitor mix), clarified by centrifugation (10 min at 15,000 g), and quantitated by Bradford analysis. Ten micrograms protein extract per lane were separated by SDS-PAGE in the presence of 1% ␤-mercaptoethanol using 10% gels (30 g protein run on 12% gels for Fig. 2 ). Rabbit polyclonal Smad antibodies (Zymed Laboratories, Inc., South San Francisco, CA), rabbit antiphospho-Smad2 (Upstate Biotechnology, Inc., Lake Placid, NY), rabbit antiactin (Sigma, St. Louis, MO), and rabbit polyclonal p15
Ink4B antibodies (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) were used to detect protein expression with enhanced chemiluminescence (Perkin-Elmer Corp., Markham, Ontario, Canada).
Growth curves
Primary human ovarian cancer cells (OC1-10) and established ovarian cancer cell lines (4 ϫ 10 4 cells/well) were plated on d 0 in growth medium in 6-well plates. On d 1, and then every third day, cells were fed medium and treated with 16 pm TGF␤1. Cells were counted using a hemacytometer over a 6-to 9-d period. The data are representative of at least three independent experiments.
Transient transfection and luciferase assays
Cells were plated in a 12-well plate at 4 ϫ 10 4 cells/well on d 0. On d 1, cells in triplicate wells were transfected with 300 ng pGL2-mod or 300 ng p3TP-lux (27) using FuGENE6 transfection reagent (Roche Molecular Biochemicals, Laval, Quebec, Canada) in normal growth media. Additional controls (negative) included cells either untransfected or transfected with 300 ng pCMV5. Cells were serum starved (growth medium with 0.2% FBS) for 8 h on d 2 and then treated with 16 pm TGF␤1 in growth medium containing 0.2% FBS. Twenty hours after addition of TGF␤1, cells were harvested and luciferase activity was determined using the Enhanced luciferase assay kit (BD PharMingen, Mississauga, Ontario, Canada). The results shown are mean data from three independent experiments.
The pGL2-mod reporter plasmid used as a negative control for the transfection experiments is a promoterless luciferase construct and is a modified version of pGL2-Basic (Promega Corp./Fisher Scientific, Nepean, Ontario, Canada). This plasmid was generated by digestion of pGL2-Basic with KpnI and HindIII, blunting the cohesive ends with T4 DNA polymerase, and religating.
Statistical analysis
Growth curve statistical analysis was done using a repeated measures two-way ANOVA with Tukey's post hoc test (P Ͻ 0.01). Statistical analysis of the transfection data was done using a t test (P Ͻ 0.01).
Results
Ovarian cancer cells express known components of the TGF␤/Smad signaling pathway. To characterize the primary ovarian cancer cells and established cell lines used for the present study, RT-PCR was done to determine whether these cells expressed components of the TGF␤/Smad signaling pathway. A total of nine primary ovarian cancer cell cultures were used for the present study (OC1-9). Data from OC1-3 are shown, and the data for OC2 and OC3 are representative of all responses to TGF␤1 treatment for OC2-9 (see below).
We found that primary ovarian cancer cells (OC1-9), CaOV3, and SkOV3 cells all express TGF␤1, T␤RI and T␤RII, Smad2, Smad3, and Smad4 (representative results are shown in Fig.  1A ). In addition, we determined that these cells also express SARA mRNA, a protein critical for regulating Smad2 and Smad3 signaling (28) . Relative levels of Smad2 and Smad4 expression were analyzed by Northern analysis (Fig. 1B) . Expression levels of Smad2 and Smad4 are elevated in the established ovarian cancer cells lines and high-passage OC1 in comparison with those in the low-passage primary ovarian cancer cells (OC2 and 3). The significance of this observation is unknown; however, it does not appear to affect Smad protein expression or signaling function (see below). To determine whether Smad transcript levels were altered by addition of TGF␤1, cells were treated with 16 pm TGF␤1 for 4 h before total RNA was harvested. After the signal was normalized vs. the GAPDH mRNA signal (graph, Fig. 1B) , the data indicate that neither Smad2 nor Smad4 transcript levels were altered with TGF␤ 1 treatment.
Expression of Smad2 and Smad3 protein was confirmed by Western analysis (Fig. 1C) . We were unable to detect Smad4 expression using commercially available antibodies (Transduction Laboratories, Lexington, KY), either from ovarian cancer cell extracts or from positive control extracts sent with the antibody.
Smad2 phosphorylation in response to exogenous TGF␤1
As an initial step to determine whether primary ovarian cancer cells have an active TGF␤ signaling pathway, we examined whether Smad2 was phosphorylated in response to TGF␤1 treatment. Cells were incubated in 0.2% FBS containing medium for at least 8 h before 30-min stimulation with 16 pm TGF␤1. In all cases the amount of phosphorylated Smad2 increased in response to TGF␤1 treatment ( Fig. 2 ; range of response 1.6-to 3.2-fold), suggesting that the TGF␤ signaling pathway is intact in primary ovarian cancer cells and established cell lines. These results were confirmed in two independent experiments, and the data in Fig. 2B are expressed as mean fold increase in Smad2 phosphorylation.
Up-regulation of endogenous genes in primary ovarian cancer cells and cell lines
Smad7 and PAI-1 are both TGF␤/Smad target genes whose transcription is rapidly induced by TGF␤ treatment (29) . Expression of Smad7 was increased in all primary ovarian cancer cells (OC1-9) and established CaOV3 and SkOV3 cell lines in response to exogenous TGF␤1 (Fig. 3) . PAI-1 was also increased in response to TGF␤1 treatment; however, the signal for PAI-1 was much weaker in CaOV3, SkOV3, and OC1 cells. The data for CaOV3, SkOV3, and OC1 cells represents a 4-d exposure of the Northern, whereas the data for OC2 and OC3 are a 24-h exposure. Data shown are representative from at least two independent experiments. The mean fold increase in Smad7 was: SkOV3: 2.9; CaOV3: 1.9; OC1: 1.7; OC2: 1.4; OC3: 1.3, whereas for PAI-1, the mean fold increase was: SkOV3: 2.5; CaOV3: 1.5; OC1: 6.6; OC2: 2.2; OC3: 1.3. Pooling the data from all of our primary ovarian cancer cultures, excluding OC1, shows that the average fold response for Smad7 is 1.5 Ϯ 0.11 (range: 1.2-1.9) and PAI-1 is 1.64 Ϯ 0.15 (range: 1.2-2.8) 4 h after TGF␤ treatment. Work by Afrakhte et al. (30) demonstrated that up-regulation of Smad7 mRNA in Mv1Lu cells occurs within 30 min of TGF␤ stimulation and peaks at 90 min. Thereafter the Smad7 mRNA levels decay but are still measurable after 4 h. We have replicated these observations in our laboratory using CaOV3 cells treated with TGF␤ and see an average 5-fold response in Smad7 transcript levels 1 h after TGF␤ treatment (Fu, Y., and M. W. Nachtigal, unpublished observation). These observations demonstrate that the TGF␤/Smad signaling pathway is functional and capable of directing expression of endogenous target genes in human ovarian cancer cells.
Reporter gene analysis of the TGF␤ signaling pathway in established ovarian cancer cells
The expression of all known TGF␤/Smad signaling components in CaOV3, SkOV3, and OC1 cells and up-regulation of endogenous TGF␤ target genes in response to TGF␤1 treatment shows that an intact pathway exists in these cells. However, we also tested the ability of ovarian cancer cells to transmit the TGF␤ signal by examining the response of a transiently transfected TGF␤/Smad reporter gene, p3TP-lux, to exogenous TGF␤1. Cells were transfected with p3TP-lux and the day after transfection treated with 16 pm TGF␤1 for 20 h. Cells were then harvested and luciferase activity was determined (Fig. 4) . Many of the primary ovarian cancer samples proved difficult to transfect, and thus we could not perform TGF␤ reporter gene experiments on these cells. All cells transfected with p3TP-lux demonstrated an 8-to 12-fold increase in luciferase activity above background in response to TGF␤1 (Fig. 4) . Negative controls (negative and pGL2-mod) gave no demonstrable activity (Ͻ0.1-fold activity relative to p3TP-lux) in the presence or absence of TGF␤1. Thus CaOV3, SkOV3, and OC1 are capable of transmitting the TGF␤/Smad signal to the nucleus to activate both endogenous and transfected target genes. pM TGF␤1 for 20 h before harvesting and measuring luciferase activity. All cells demonstrated a basal level of p3TP-lux activity in growth medium containing 10% FBS that was increased 8-to 12-fold in the presence of TGF␤1. Luciferase activity from negative controls (negative and pGL2-mod) was less than 0.1-fold activity relative to p3TP-lux in the presence or absence of TGF␤1. Luciferase activity was measured in relative light units and is reported as fold difference from basal p3TP-lux activity. Statistical analysis was done using a t test (*, P Ͻ 0.005). Bars indicate SEM.
Effect of TGF␤ on ovarian cancer cell proliferation
To further confirm TGF␤ signaling activity, we tested the effect of TGF␤1 treatment on growth of ovarian cancer cell cultures. A total of 10 primary ovarian cancer cell cultures were used for the growth study (OC1-10). Data from OC1-3 are shown, and the data for OC2 and 3 are representative of all responses to TGF␤1 treatment for OC2-10. Beginning 24 h after cells were seeded, cultures were treated with 16 pm TGF␤1 and the effect on cell proliferation determined over the next 6 -9 d (Fig. 5) . OC2-9 cells were growth inhibited by TGF␤1 treatment (Fig. 5) ; Mv1Lu cells are known to stop growing in response to TGF␤ treatment and were used as control cultures (data not shown; 31). We found that 16 pm TGF␤1 was sufficient to inhibit growth of the primary cells. By contrast, OC1 and the established cell lines CaOV3 and SkOV3 (Fig. 5) continued to proliferate in the presence of TGF␤1 (16 pm-1.6 nm). Cell viability was not affected by treatment with TGF␤1 as determined by the trypan blue dye exclusion technique (data not shown). The graphs show representative data from three separate experiments. Statistical analysis was done using a repeated measures two-way ANOVA with Tukey's post hoc test (*, P Ͻ 0.01). These data show that the majority of ovarian cancer cells (90%) stop growing in response to TGF␤1 treatment, in contrast to OC1 and the established cell lines.
Growth inhibition by TGF␤ is partially mediated by mod- ulating levels and activities of cell cycle regulatory proteins, such as p15 Ink4B (CDKN2B) (32, 33) . Indeed, the promoter for the p15
Ink4B gene contains positive TGF␤/Smad response elements, and p15
Ink4B transcription is rapidly up-regulated in response to TGF␤ treatment (34, 35) . Northern analysis reveals that in ovarian cancer cells, which are growth inhibited by TGF␤1, p15
Ink4B mRNA increases when cells are incubated with TGF␤1 (OC2, OC3, Fig. 6A ; OC4 -9 not shown). The increase in mRNA correlates with increasing p15 protein levels (Fig. 6B) . By contrast, p15
Ink4B mRNA and protein was not detected in the OC1, CaOV3, and SkOV3 cells, which are insensitive to TGF␤1. The gene for p15 Ink4B is deleted in SkOV3 cells (36) . Using genomic PCR and Southern analysis we did not detect p15
Ink4B genomic DNA from OC1, CaOV3, and SkOV3 cells (data not shown); however, p15
Ink4B genomic DNA was detected in the TGF␤1-sensitive OC samples (OC2-9; data not shown).
Discussion
Our work is the first to show that all known components of the TGF␤/Smad signaling pathway, including TGF␤1, T␤RI, T␤RII, Smad2, -3, -4, and SARA, are expressed and remain functional in primary human ovarian cancer cell cultures and two established ovarian cancer cell lines, SkOV3 and CaOV3. Furthermore, our analysis revealed that 9 of 10 primary ovarian cancer cell cultures isolated from ascite fluid remain sensitive to the growth inhibitory effects of TGF␤1. The ability of TGF␤1 to block ovarian cancer cell proliferation is likely to be partially mediated by the observed increase in p15
Ink4B production in response to TGF␤1 treatment. The failure of CaOV3, SkOV3, and OC1 to respond to the growthinhibitory effects of TGF␤1 is not owing to defects in the TGF␤/Smad signaling pathway because we showed that these cells can up-regulate a transfected TGF␤/Smadresponsive reporter gene. In addition, all primary and established cells can increase mRNA levels of endogenous Smad7 and PAI-1, demonstrating that human ovarian cancer cells maintain a functional TGF␤/Smad signaling pathway.
Previous reports examining the effect of TGF␤ on ovarian cancer cell proliferation have yielded contradictory results. Initial studies showed that most established ovarian cancer cell lines are resistant to the antiproliferative effects of TGF␤ (4, 33) . Many established cell lines have accumulated significant genetic alterations, including loss of p53 and p15 Ink4B and do not accurately represent primary ovarian cancer cells (36, 37) . Loss of heterozygosity of p15
Ink4B is shown to occur in approximately 10% of primary ovarian tumors and may contribute to the development of a proportion of human ovarian cancer (38) . Indeed, the inability of CaOV3, SkOV3, and OC1 cells to respond to the antiproliferative effects of TGF␤1 may be because of defects in TGF␤/Smad targets important for cell cycle regulation, including p21
Cip1 , p27 Kip1 , and c-myc; however, we hypothesized that the observed effect is owing to deletion in p15
Ink4B in these cells. Hurteau et al. (11) demonstrated that primary ovarian cancer cells isolated from ascites remain sensitive to the growth-inhibitory effects of TGF␤1, which agrees with the present study. By contrast, results from Yamada et al. (16) suggest that ovarian cancer cell cultures isolated from solid tumors, which express functional TGF␤ receptors, can be insensitive to the antiproliferative effects of TGF␤1. Yamada et al. (16) showed that 5 of 23 cultures were growth inhibited, 7 of 23 were growth stimulated, and 11 of 23 showed no significant change in cell growth. In these studies, proliferation was measured over a 48-h time course using the 3-(4,5-dimethylthiazol-2-yl)-2,5-dimethyltetrazolium bromide growth assay, whereas our cell proliferation studies were conducted over a 6-to 9-d time course. Indeed, we saw little change in cell number at 48 h, and significant differences occurred only at later time points, typically at d 4 -5. In agreement with our data, Yamada et al. (16) did examine the growth-inhibitory effects of TGF␤1 on one primary cell culture isolated from ascites and saw growth inhibition in response to TGF␤1 treatment. It remains possible that contradictory results may reflect differences in the biology of ovarian cancer cells originating from different sites (ascites vs. solid tumor explants).
Recent literature suggests that TGF␤ receptor mutants may contribute to the development of some ovarian tumors. Lynch et al. (18) identified 5 of 24 sporadic ovarian tumors with missense mutations in the conserved serine/threonine kinase or transmembrane domain of T␤RII; these results correlated with a decrease or loss of T␤RII protein production. A similar study by Wang et al. (19) failed to detect any T␤RII mutations in their patient population; however, they determined that 10 of 32 (31.3%) primary ovarian cancer samples failed to express T␤RI. More recently, Chen et al. (20) reported that 33% of archival primary ovarian cancer samples harbor missense mutations in the coding region of T␤RI. Groups that have examined the genes for Smad2, -3, and -4 discovered some sequence polymorphisms but no putative inactivating mutations in ovarian cancer tissues (19, 39) . Although these studies indicate that missense mutations are frequently observed in coding and noncoding regions of the T␤RI and T␤RII genes, functional biochemical analysis was not done to determine whether these mutations affect TGF␤/ Smad signaling. We did not find any evidence of disrupted TGF␤/Smad signaling in ovarian cancer cells isolated from patient ascites. These data suggest that mutations affecting the TGF␤ signaling pathway, although occurring in some human ovarian tumors, are not a universal hallmark of ovarian cancer.
Ovarian cancer cells receive a myriad of signals from molecules present in ascitic fluid or in the tumor microenvironment, and the interpretation of these signals ultimately results in the cellular response (e.g. grow, die, migrate, invade). With respect to TGF␤/Smad signaling, target gene transcription is dictated by nuclear accumulation of the activated Smad complex and subsequent interaction with nuclear transcription factors and cofactors on the target gene promoter (40) . In addition to signals from TGF␤-like molecules, nuclear accumulation of Smad proteins can be modulated by Rasactivated Erk kinases (reviewed in Ref. 40) . Hyperphosphorylation of Smad2 and -3 by Erk kinases, stimulated by epidermal growth factor (EGF), hepatocyte growth factor, or oncogenic Ras, blocks their nuclear translocation and inhibits TGF␤ signaling. In addition, EGF can up-regulate inhibitory Smad6 and -7 mRNA (30), thus decreasing expression of endogenous gene targets. EGF and hepatocyte growth factor are autocrine growth factors produced by ovarian cancer cells that stimulate their proliferation, migration, and invasiveness (41, 42) . Indeed, EGF is typically elevated in serum from women with epithelial ovarian cancer, compared with healthy age-matched women (42a) Although ovarian cancer cells isolated from ascites remain responsive to the antiproliferative effects of TGF␤1, we hypothesized that this cytostatic activity is modulated by additional environmental cues affecting Smad signaling activity, such as EGF, allowing the cells to alter their normal cellular response to TGF␤ in vivo. Precedence for this idea exists with the discovery that oncogenic Ras in mammary epithelial cells blocks the antiproliferative effects of TGF␤ and reprograms the cells to become invasive and metastatic in response to TGF␤ (43) .
The role that TGF␤ biology plays in ovarian tumorigenesis is unclear. We show that the TGF␤/Smad signaling pathway is functional in ovarian cancer cells and that in vitro these cells stop proliferating in response to TGF␤1 treatment. In marked contrast, in vivo ovarian cancer cells continue to proliferate despite the presence of high amounts of TGF␤ in ascite fluid [median concentration 5.4 ng/ml TGF␤1 (44)]. Many human tumors, including ovarian cancers (15, 45) , overexpress TGF␤ mRNA and protein in vivo, and increased expression correlates with advanced stages of the disease. Cells that escape the growth-inhibitory effects of TGF␤ and produce large amounts of the protein may have a selective advantage for tumor cell survival because of the positive angiogenic and immunosuppressive effects that allow TGF␤ to promote tumor growth (13, 14) . In addition, TGF␤ enhances the invasive properties of ovarian cancer cells, most likely through upregulation of cellular matrix metalloproteinases (21) . Thus, TGF␤ may play a dual role in OSE biology. Under nonpathologic conditions, normal OSE cells are growth inhibited by TGF␤ through an autocrine loop. Once tumorigenesis is initiated, however, TGF␤ signaling may be altered to enhance the metastatic process.
